#USA #Chicago #CDMO #ESTEVE #Regis Technologies

ESTEVE Expands Its Reach in the U.S. Market with Regis Technologies Acquisition

In a strategic move aimed at broadening its footprint in the U.S. pharmaceutical landscape, ESTEVE has successfully acquired Regis Technologies, a renowned Chicago-based Contract Development and Manufacturing Organization (CDMO). This pivotal acquisition allows ESTEVE to enhance its capabilities in contract development and manufacturing of active pharmaceutical ingredients (APIs), covering every phase from preclinical to commercial production.

The Significance of the Acquisition

For over 65 years, Regis Technologies has established itself as a leader in the API sector, offering a diverse array of services that include process research and development, analytical stability, and commercial scale API manufacturing compliant with current Good Manufacturing Practices (cGMP). This acquisition not only augments ESTEVE’s service range but also fortifies its operational presence in the critical U.S. market, allowing it to better support its clientele.

Joan Petit, Operations Director of ESTEVE and General Manager of Esteve CDMO, expressed pride in this expansion, stating, "We are thrilled to enhance our CDMO team and services for pharmaceutical innovators. This acquisition significantly boosts our development and manufacturing capabilities and adds to our skilled workforce of nearly 70 professionals."

ESTEVE and Regis Technologies: A Complementary Partnership

ESTEVE’s integration of Regis Technologies under the Esteve CDMO brand is a testament to both companies' dedication to providing top-notch services in the pharmaceutical sector. The enhanced capabilities include advanced technologies, such as spray drying and the production of high-potency active pharmaceutical ingredients (HPAPI). This will ultimately enable ESTEVE to accompany clients throughout the entire drug development lifecycle, improving efficiency and speed to market.

Staffan Schüberg, CEO of ESTEVE, emphasized the strategic nature of this acquisition, noting, "The U.S. market is paramount for ESTEVE. This acquisition marks a vital step forward in our mission to improve lives by bolstering our CDMO capabilities and broadening our integrated service offerings in this region."

Moreover, Scott Aladeen, President and CEO of Regis Technologies, highlighted the cultural alignment between the two entities, remarking, "We are pleased to join an organization that shares our values—an established family business with over 90 years of expertise, dedicated to enhancing the lives of individuals while focusing on delivering long-term value to clients."

ESTEVE’s Broader Vision

The acquisition of Regis Technologies adds another dimension to ESTEVE’s dual business model, which includes both API development and manufacturing for third-party clients (CDMO) and a robust pharmaceutical business offering specialized medications across Europe and the U.S. With production facilities located in Spain, Mexico, China, and now the United States, ESTEVE is well positioned to respond to the dynamic needs of the pharmaceutical industry.

Founded in 1929 and headquartered in Barcelona, ESTEVE is a global pharmaceutical company committed to improving quality of life. It serves to address unmet therapeutic needs through innovative and specialized solutions. Their facilities in Spain, Mexico, and China uphold the highest standards of quality and efficiency, which is integral to their mission.

Conclusion

In conclusion, ESTEVE's acquisition of Regis Technologies not only symbolizes a strategic expansion into the U.S. market but also reinforces their commitment to excellence in pharmaceutical development and manufacturing. As both entities combine their strengths, they are set to make significant contributions in the field of drug development and manufacturing that ultimately enhance patient outcomes and streamline pharmaceutical advancements.

For more information about ESTEVE and its comprehensive services, visit ESTEVE's website.